Storia in 2 fonti

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Raccontata da

cnbc.com

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo1 mesi fa

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

originale

biopharmadive.com1 mesi fa

Novo hikes guidance on Wegovy pill’s fast sales start

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

Leggi questa versione → originale

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance

Confronto fonti

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance

Novo hikes guidance on Wegovy pill’s fast sales start

Timeline cronologica

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance

Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance

Novo hikes guidance on Wegovy pill’s fast sales start